GlassScriptPhysician profile
Todd J Harvey
NPI 1245292143
$1,359.17
in general payments reported to CMS, 2019-2025
19 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $113 · 2021: $241 · 2022: $280 · 2023: $145 · 2024: $148 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.82 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $206.43 | 2019-2022 | |
| Abbvie INC. | $145.29 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $144.15 | 2022-2025 | Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.66 | 2019-2021 | |
| Alcon Vision LLC | $104.96 | 2019-2025 | Tryptyr |
| New World Medical,INC. | $90.64 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Horizon Therapeutics Plc | $81.16 | 2021-2023 | Tepezza |
| Glaukos Corporation | $68.95 | 2022 | |
| Amgen INC. | $58.52 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $53.09 | 2019 | |
| Allergan, INC. | $43.60 | 2019-2021 | |
| Oyster Point Pharma, INC. | $40.31 | 2022 | |
| Sun Pharmaceutical Industries INC. | $39.03 | 2019 | |
| Shire North American Group INC | $36.10 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $31.38 | 2024 | Xdemvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $20.52 | 2021 | |
| Biotissue Holdings INC. | $19.91 | 2025 | |
| Kala Pharmaceuticals, INC. | $18.77 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.